Label-retaining liver cancer cells are relatively resistant to sorafenib

OBJECTIVE: The standard therapy for advanced hepatocellular carcinoma (HCC) is sorafenib, with most patients experiencing disease progression within 6 months. Label-retaining cancer cells (LRCC) represent a novel subpopulation of cancer stem cells (CSC). The objective was to test whether LRCC are re...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Gut
Prif Awduron: Xin, Hong-Wu, Ambe, Chenwi M, Hari, Danielle M, Wiegand, Gordon W, Miller, Tyler C, Chen, Jin-Qiu, Anderson, Andrew J, Ray, Satyajit, Mullinax, John E, Koizumi, Tomotake, Langan, Russell C, Burka, Douglas, Herrmann, Michelle A, Goldsmith, Paul K, Stojadinovic, Alexander, Rudloff, Udo, Thorgeirsson, Snorri S, Avital, Itzhak
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2013
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6993136/
https://ncbi.nlm.nih.gov/pubmed/23411027
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/gutjnl-2012-303261
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg